NPS Intelligence (beta)

Disclosed NPS & retention by vertical

Verticals  /  Pharma, medtech & health distribution  /  NeoGenomics, Inc.
77
Latest disclosed NPS
15 Aug 2026
29
NPS entries
23 with a number
97%
Retention
19 Feb 2019
2016–26
Years covered
33 entries in all

In their words

“Our net promoter score of 79 reflects strong physician satisfaction among our current customer base with our NPS score continuing to improve in 2025, even with record test volumes.”
— Anthony P. Zook, President and CEO, NeoGenomics, Inc. · Earnings call, Q4 2025 · 17 Feb 2026
“The trust our partners have in us to deliver on turnaround time and meet our commitments has once again improved our Net Promoter Score to 74 in 2024, up from 70 in 2023.”
— Warren Stone, Chief Commercial Officer, NeoGenomics, Inc. · Earnings call, Q4 2024 · 18 Feb 2025
“As a result of our increased coverage, clinical support, and patient-centric mentality, we maintained our customer experience leadership in the market with a three point improvement in net promoter score, which is now at 70.”
— Chris Smith, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q4 2023 · 20 Feb 2024

Disclosed NPS over time

Every Net Promoter Score NeoGenomics, Inc. has published, by date.

506070802019202020212022202420252026

NPS disclosures (29)

Search the database →

15 Aug 2026
NPS77

NeoGenomics reported Net Promoter Scores in the high 70s across both segments as it expands its commercial representative force.

— reported by tipranks.com · 15 Aug 2026
tipranks.com ↗
29 Jul 2026
NPS78

NeoGenomics achieved a Net Promoter Score of 78 in a June 2026 study.

— reported by investing.com · 29 Jul 2026
investing.com ↗
28 Jul 2026
NPSProgram

They also lead to an industry-leading customer experience as evidenced by our Net Promoter Score in the high 70s across both pathology and oncology.

— Warren Stone, Chief Operating Officer, NeoGenomics, Inc. · Earnings call, Q2 2026 · 28 Jul 2026
Earnings call, Q2 2026 ↗
6 Apr 2026
NPS79

Improved our Net Promoter Score to 79, up from 74 in 2024, reflecting strong physician satisfaction among our current customer base 2025 Annual Report — 3 $ in Thousands 2022 2023 2024 2025 Revenue $509,728 $591,643 $660,566 $727,332 % Growth 5.2% 16.1%…

— NeoGenomics, Inc. · SEC annual report · filed 6 Apr 2026
SEC annual report ↗
17 Feb 2026
NPS79

Our net promoter score of 79 reflects strong physician satisfaction among our current customer base with our NPS score continuing to improve in 2025, even with record test volumes.

— Anthony P. Zook, President and CEO, NeoGenomics, Inc. · Earnings call, Q4 2025 · 17 Feb 2026
Earnings call, Q4 2025 ↗
8 Apr 2025
NPS74

…Improved our Net Promoter Score to 74, up from 70 in 2023 •

— NeoGenomics, Inc. · SEC annual report · filed 8 Apr 2025
SEC annual report ↗
18 Feb 2025
NPS74

The trust our partners have in us to deliver on turnaround time and meet our commitments has once again improved our Net Promoter Score to 74 in 2024, up from 70 in 2023.

— Warren Stone, Chief Commercial Officer, NeoGenomics, Inc. · Earnings call, Q4 2024 · 18 Feb 2025
Earnings call, Q4 2024 ↗
20 Feb 2024
NPS70

As a result of our increased coverage, clinical support, and patient-centric mentality, we maintained our customer experience leadership in the market with a three point improvement in net promoter score, which is now at 70.

— Chris Smith, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q4 2023 · 20 Feb 2024
Earnings call, Q4 2023 ↗
14 Apr 2022
NPS62

Our latest Net Promoter Score Survey yielded a 62, continuing our track record of delivering elite service levels to our customers. We are proud of the quality of the service that our teams continued to deliver during the year.

— NeoGenomics, Inc. · SEC 8-K filing · filed 14 Apr 2022
SEC 8-K filing ↗
23 Feb 2022
NPS60

I’m also pleased to share that Neo again achieved a net promoter score in excess of 60, a world-class result. I want to thank our committed employees, who are the key to our strong customer relationships and our track record of delivering elite service.

— Mark Mallon, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q4 2021 · 23 Feb 2022
Earnings call, Q4 2021 ↗
10 Aug 2021
NPS66

…and appropriate biomarkers leads to great care at a value We Are Focused on The Customer NOTES: 1,055 respondents 17 Best-in-class net promoter score Q4 2020 Clinical Client Survey How likely is it that you would recommend this company to a friend or…

— NeoGenomics, Inc. · SEC 8-K filing · filed 10 Aug 2021
SEC 8-K filing ↗
6 Aug 2021
NPSProgram

This consistent dedication has translated into industry leading turnaround times in many of our test modalities and is also reflected in both our strong Net Promoter Scores and the extremely high customer retention rate.

— Mark Mallon, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q2 2021 · 6 Aug 2021
Earnings call, Q2 2021 ↗
6 May 2021
NPS66

…and appropriate biomarkers leads to great care at a value We Are Focused on The Customer NOTES: 1,055 respondents 16 Best-in-class net promoter score Q4 2020 Clinical Client Survey How likely is it that you would recommend this company to a friend or…

— NeoGenomics, Inc. · SEC 8-K filing · filed 6 May 2021
SEC 8-K filing ↗
15 Apr 2021
NPS67

• Improved net promoter score to 67; • Achieved Clinical revenue growth of approximately 6% in a COVID impacted environment.

— NeoGenomics, Inc. · SEC proxy statement · filed 15 Apr 2021
SEC proxy statement ↗
25 Feb 2021
NPS66

…biomarkers leads to great care at a value Exhibit 99.1 We Are Focused on The Customer NOTES: 1,055 respondents 16 Best-in-class net promoter score Q4 2020 Clinical Client Survey How likely is it that you would recommend this company to a friend or…

— NeoGenomics, Inc. · SEC 8-K filing · filed 25 Feb 2021
SEC 8-K filing ↗
5 Jan 2021
NPS66

…And Appropriate Biomarkers Leads To Great Care At A Value We Are Focused on The Customer NOTES: 1,055 respondents 17 Best in Class Net Promoter Score Q4 2020 Clinical Client Survey How likely is it that you would recommend this company to a friend or…

— NeoGenomics, Inc. · SEC 8-K filing · filed 5 Jan 2021
SEC 8-K filing ↗
29 Oct 2020
NPS67

…year-over-year 39% year-over-year Q3 of 2020 increase in backlog Pharma revenue growth 12 Focused on Customer Satisfaction Net Promoter Score Q2 2020 Clinical Client Survey How likely is it that you would recommend this company to a friend or colleague?

— NeoGenomics, Inc. · SEC 8-K filing · filed 29 Oct 2020
SEC 8-K filing ↗
31 Jul 2020
NPS67

Not at all likely Neutral Extremely likely 0 0 1 2 3 4 5 6 7 8 9 10 -50 50 Detractor Passive Promoter +67 NPS 7% 19% 74% -100 100 % Promoters - % Detractors = NPS ( Net Promoter Score) NOTES: 1,423 respondents 28 questions + comments 13 Culture Is At…

— NeoGenomics, Inc. · SEC 8-K filing · filed 31 Jul 2020
SEC 8-K filing ↗
28 Jul 2020
NPSProgram

We surveyed clients in the midst of the pandemic and received our highest response rate and highest score ever with a score that is nearly tenfold higher than the average score for our peer group.

— Doug VanOort, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q2 2020 · 28 Jul 2020
Earnings call, Q2 2020 ↗
30 Apr 2020
NPS60

Not at all likely Neutral Extremely likely 0 0 1 2 3 4 5 6 7 8 9 10 -50 50 Detractor Passive Promoter +60 NPS 7% 26% 67% -100 100 % Promoters - % Detractors = NPS ( Net Promoter Score) NOTES: Survey Period: November 11th, 2019 to January 10th, 2020 951…

— NeoGenomics, Inc. · SEC 8-K filing · filed 30 Apr 2020
SEC 8-K filing ↗
2 Mar 2020
NPS60

…Q4 adding $12M to backlog increase in backlog Pharma revenue growth sequentially 12 Focused on Customer Satisfaction Net Promoter Score Q1 2020 Clinical Client Survey How likely is it that you would recommend this company to a friend or colleague?

— NeoGenomics, Inc. · SEC 8-K filing · filed 2 Mar 2020
SEC 8-K filing ↗
31 Oct 2019
NPS63

…in diluted shares — — Adjusted diluted shares outstanding (non-GAAP) 104,500 104,500 26 Focused on Customer Satisfaction Net Promoter Score Q2 2019 Clinical Client Survey How likely is it that you would recommend this company to a friend or colleague?

— NeoGenomics, Inc. · SEC 8-K filing · filed 31 Oct 2019
SEC 8-K filing ↗
2 Aug 2019
NPS63

…4,000 — Adjusted diluted shares outstanding (non-GAAP) 104,500 104,500 27 Exhibit 99.1 Focused on Customer Satisfaction Net Promoter Score Q2 2019 Clinical Client Survey How likely is it that you would recommend this company to a friend or colleague?

— NeoGenomics, Inc. · SEC 8-K filing · filed 2 Aug 2019
SEC 8-K filing ↗
20 May 2019
NPS59

…stock-based compensation 2,139 1,624 Adjusted EBITDA (non-GAAP) $ 13,759 $ 9,238 26 Focused on Customer Satisfaction Net Promoter Score Q4 2018 Clinical Client Survey How likely is it that you would recommend this company to a friend or colleague?

— NeoGenomics, Inc. · SEC 8-K filing · filed 20 May 2019
SEC 8-K filing ↗
26 Apr 2019
NPSProgram

Client satisfaction for both divisions, measured by Net Promoter Scores, were considered world class, and client retention rates continued to be above 98%.

— NeoGenomics, Inc. · SEC 8-K filing · filed 26 Apr 2019
SEC 8-K filing ↗
19 Feb 2019
NPS59

We are quite proud that with approximately 2000 responses to our customer surveys during 2018, our net promoter scores ranged from 59 to 60.

— Douglas VanOort, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q4 2018 · 19 Feb 2019
Earnings call, Q4 2018 ↗
7 Nov 2018
NPSProgram

…LDT & IVD assays 10 Net Promoter Score Overview: • Survey Opened June 4th •

— NeoGenomics, Inc. · SEC 8-K filing · filed 7 Nov 2018
SEC 8-K filing ↗
25 Jul 2017
NPS54

Our Net Promoter Score or NPS was a record high 54. You may be aware of the Net Promoter Score; it was developed by Bain & Company, and is a tool for gauging the loyalty of a firm's customer relationships.

— Doug VanOort, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q2 2017 · 25 Jul 2017
Earnings call, Q2 2017 ↗
27 Apr 2016
NPSProgram

Our customer survey results the other day -- we measure something call the Net Promoter Score. Many of our clients rated us very, very highly and are essentially promoters of our service.

— Douglas VanOort, CEO, NeoGenomics, Inc. · Earnings call, Q1 2016 · 27 Apr 2016
Earnings call, Q1 2016 ↗

Retention disclosures (4)

Open in the retention database →

18 Feb 2021
Retentionup

Neo4j reported impressive global customer retention and growth in 2020, with a customer base of almost 800 across numerous industries.

— reported by finance.yahoo.com · 18 Feb 2021
finance.yahoo.com ↗
19 Feb 2019
Retention97%

Retention rate: 97% (Q4 2018) — “our retention rate of customers is in the very high 90 and we don't expect to lose customers”

— Douglas VanOort, Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q4 2018 · 19 Feb 2019
Earnings call, Q4 2018 ↗
22 Feb 2018
Retention97.5%

NeoGenomics reported an overall customer retention rate of 97.5 percent in 2017.

— reported by martechseries.com · 22 Feb 2018
martechseries.com ↗
21 Feb 2018
Retention97.5%

Retention rate: 97.5% (Q4 2017) — “our overall customer retention rate during the past year was 97.5%”

— Doug VanOort, Chairman and Chief Executive Officer, NeoGenomics, Inc. · Earnings call, Q4 2017 · 21 Feb 2018
Earnings call, Q4 2017 ↗

Lighthouse companies in Pharma, medtech & health distribution

The whole vertical →

About these figures

Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.

NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.